# Identification of high-performing antibodies for SPARC-related modular calcium-binding protein 1 (SMOC-1) for use in Western Blot and immunoprecipitation

## TL;DR

This paper identifies reliable antibodies for SMOC-1, a protein linked to Alzheimer's disease, to help improve research consistency and diagnostic exploration.

## Contribution

The study evaluates and identifies high-performing commercial antibodies for SMOC-1 suitable for Western blot and immunoprecipitation.

## Key findings

- Seven commercial SMOC-1 antibodies were tested using a standardized protocol.
- Successful antibodies for Western blot and immunoprecipitation were identified.
- The findings aim to guide researchers in selecting appropriate antibodies for their studies.

## Abstract

SPARC-related modular calcium-binding protein 1, otherwise known as SMOC-1, is a secreted glycoprotein involved in various cell biological processes including cell-matrix interactions, osteoblast differentiation, embryonic development, and homeostasis. SMOC-1 was found to be elevated in asymptomatic Alzheimer’s disease (AD) patient cortex as well as being enriched in amyloid plaques and in AD patientcerebrospinal fluid, arguing for SMOC-1 as a promising biomarker for AD. Having access to high-quality SMOC-1 antibodies is crucial for the scientific community. It can ensure the consistency and reliability of SMOC-1 research, and further the exploration of its potential as both a therapeutic target or diagnostic marker.. In this study, we characterized seven SMOC-1 commercial antibodies for Western blot and immunoprecipitation, using a standardized experimental protocol based on comparing read-outs in knockout cell lines and isogenic parental controls. We identified successful antibodies in the tested applications and encourage readers to use this report as a guide to select the most appropriate antibody for their specific needs.